Growth potential Small team with strong backing and global R&D footprint suggests a lean, scalable partnership model. There is potential to offer contract research, development collaboration, or technology licensing to accelerate their small molecule programs in oncology and metabolic diseases.

Global collaboration Operations in the US and China indicate openness to cross-border partnerships. Propose joint development agreements, CRO/CMO services, or regional regulatory advisory to support clinical milestones and global commercialization readiness.

Financially supported Backed by Fosun Pharma and yet reporting sub-$1M revenue, presenting an opportunity to tailor flexible, milestone-based deals, discounted early-stage services, or credit-friendly financing for research and development activities.

Clinical focus Emphasis on cancer and metabolic disease small molecules suggests targeting pharma partners with oncology metabolism programs, screening collaborations, and access to proprietary assay platforms or high-throughput screening capabilities to de-risk early discovery.

Technology fit Tech stack and web presence imply a modern but compact operation. Position offerings around cloud-based collaboration tools, data analytics for drug discovery, and scalable digital solutions that fit a small team while enabling rapid project onboarding.